|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.510 USD | +16.24% |
|
+27.55% | -40.88% |
Company Valuation: Aligos Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 505.9 | 40.8 | 49.75 | 147.9 | 57.35 | 34.1 | - | - |
| Change | - | -91.93% | 21.95% | 197.2% | -61.21% | -40.55% | - | - |
| Enterprise Value (EV) 1 | 505.9 | 40.8 | 49.75 | 147.9 | -20.46 | 10.81 | -248.1 | -140 |
| Change | - | -91.93% | 21.95% | 197.2% | -113.83% | 152.86% | -2,393.98% | 43.57% |
| P/E | -3.69x | -0.42x | -0.49x | -1.9x | -3.8x | -0.79x | -1.29x | -2.44x |
| PBR | 2.74x | - | - | - | 1.72x | -7.87x | 0.68x | 1.2x |
| PEG | - | 0x | 0x | 0x | 0x | -0x | 0x | 0.1x |
| Capitalization / Revenue | 116x | 2.93x | 5.33x | 37.5x | 26.2x | 1.57x | 6.82x | 0.52x |
| EV / Revenue | 116x | 2.93x | 5.33x | 37.5x | -9.36x | 0.5x | -49.6x | -2.15x |
| EV / EBITDA | -3.94x | - | - | - | 0.23x | -0.1x | 2.02x | 1.06x |
| EV / EBIT | -3.94x | -0.42x | -0.56x | -1.66x | 0.23x | -0.11x | 1.93x | 1.47x |
| EV / FCF | -4.34x | - | - | - | 0.25x | -0.12x | 2.11x | 1.16x |
| FCF Yield | -23% | - | - | - | 405% | -802% | 47.5% | 86.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -80.5 | -56.25 | -34 | -20.94 | -2.45 | -6.98 | -4.255 | -2.261 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 4.359 | 13.91 | 9.338 | 3.945 | 2.186 | 21.68 | 5 | 65.1 |
| EBITDA 1 | -128.3 | - | - | - | -87.06 | -112.7 | -122.9 | -132.1 |
| EBIT 1 | -128.3 | -97.58 | -88.13 | -89.15 | -87.98 | -100.6 | -128.2 | -95.22 |
| Net income 1 | -128.3 | -96.05 | -87.68 | -131.2 | -24.19 | -93.85 | -124.2 | -91.85 |
| Net Debt 1 | - | - | - | - | -77.81 | -23.28 | -282.2 | -174.1 |
| Reference price 2 | 296.750 | 23.822 | 16.600 | 39.840 | 9.320 | 5.510 | 5.510 | 5.510 |
| Nbr of stocks (in thousands) | 1,705 | 1,713 | 2,997 | 3,712 | 6,154 | 6,188 | - | - |
| Announcement Date | 3/10/22 | 3/9/23 | 3/12/24 | 3/10/25 | 3/5/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.79x | 0.5x | -0.1x | -.--% | 34.1M | |
| 33.27x | 5.94x | 17.68x | 0.96% | 48.7B | |
| -22.15x | 304.02x | -19.9x | -.--% | 42.05B | |
| 29.93x | 2.99x | 12.91x | -.--% | 38.26B | |
| 43.85x | 4.94x | 27.58x | -.--% | 37.5B | |
| 29.67x | 8.57x | 21.53x | 0.39% | 31.44B | |
| 33.27x | 5.44x | 24.74x | -.--% | 16.33B | |
| 23.25x | 2.04x | 8.83x | 1.16% | 13.98B | |
| 53.86x | 3.78x | 14.82x | -.--% | 12.68B | |
| Average | 24.91x | 37.58x | 12.01x | 0.28% | 26.77B | |
| Weighted average by Cap. | 24.74x | 57.31x | 12.22x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALGS Stock
- Valuation Aligos Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
